Schneider Securities, Inc. Reiterates Its Buy Rating of Drugmax.com
DENVER, Nov. 20 /PRNewswire/ -- Schneider Securities, Inc. updates its research on Drugmax.com (Nasdaq: DMAX) and reiterates it's BUY rating as well as it's 12-month price target of $12.00 per share. In addition, on the strength of the company's strong first half of fiscal 2002, the update addresses increases to earnings estimates reflected in the initial coverage of April 16, 2001. These estimates include an increase for the third quarter of fiscal 2002 ended December 31, 2001 from $0.02 per share to $0.09, as well as an increase for the full 2002 fiscal year from $0.02 to $0.38.
Information and statements contained herein, other than historical information, should be considered forward looking, which involve risk and uncertainties. Schneider Securities Inc., its officers, directors and affiliates may maintain positions in the securities referenced, which may change at any time without notice. Schneider Securities, Inc. is a Market Maker in these securities. The securities referenced are speculative in nature and may not be suitable for your investment objective. Additional information is available upon request.
For further information, please contact: Dave Lavigne of Schneider Securities, Inc., +1-303-771-9600. |
